{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:30:01Z","timestamp":1776846601699,"version":"3.51.2"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10147-026-02996-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:21:00Z","timestamp":1774452060000},"page":"834-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2047-496X","authenticated-orcid":false,"given":"Takuma","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-8915","authenticated-orcid":false,"given":"Yoichiro","family":"Tohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9007-435X","authenticated-orcid":false,"given":"Kei","family":"Daizumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-2457","authenticated-orcid":false,"given":"Satoshi","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-3156","authenticated-orcid":false,"given":"Keita","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Morinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-5892","authenticated-orcid":false,"given":"Shuichi","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8974-9218","authenticated-orcid":false,"given":"Junya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3172-2482","authenticated-orcid":false,"given":"Motoo","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9995-565X","authenticated-orcid":false,"given":"Yoshiyuki","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2229-0948","authenticated-orcid":false,"given":"Noriyoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9266-782X","authenticated-orcid":false,"given":"Mikio","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Chu-Shikoku Japan Urological Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2996_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2996_CR2","unstructured":"The National Cancer Institute Surveillance, Epidemiology and Ends Results Program (2024) Cancer Stat Facts: Prostate. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed 29 Jan 2026"},{"key":"2996_CR3","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1007\/s10147-024-02575-3","volume":"29","author":"T Sasaki","year":"2024","unstructured":"Sasaki T, Higashi T, Inoue T (2024) Urological cancer statistics on incidence from 1975 to 2019 and mortality from 1958 to 2022 in Japan. Int J Clin Oncol 29:1088\u20131095","journal-title":"Int J Clin Oncol"},{"key":"2996_CR4","unstructured":"National Cancer Center Cancer Information Service (NCC-CIS) (2024) Cancer Statistics in Japan 2024. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2024_en.html. Accessed 29 Jan 2026"},{"key":"2996_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352\u2013360","journal-title":"N Engl J Med"},{"key":"2996_CR6","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37:2974\u20132986","journal-title":"J Clin Oncol"},{"key":"2996_CR7","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294\u20132303","journal-title":"J Clin Oncol"},{"key":"2996_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132\u20131142","journal-title":"N Engl J Med"},{"key":"2996_CR9","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer,Version 4.2024. https:\/\/www.nccn.org\/.\u3000Accessed 16 Nov 2024"},{"key":"2996_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147\u20131154","journal-title":"Lancet"},{"key":"2996_CR11","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit R, de Bono J, Sternberg CN et al (2019) Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med 381:2506\u20132518","journal-title":"N Engl J Med"},{"key":"2996_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/bjs.4038","volume":"90","author":"DC McMillan","year":"2003","unstructured":"McMillan DC, Canna K, McArdle CS (2003) Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90:215\u2013219","journal-title":"Br J Surg"},{"key":"2996_CR13","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1080\/07853890.2023.2192047","volume":"55","author":"CL Zhang","year":"2023","unstructured":"Zhang CL, Gao MQ, Jiang XC et al (2023) Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence. Ann Med 55:1294\u20131307","journal-title":"Ann Med"},{"key":"2996_CR14","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.21873\/anticanres.16572","volume":"43","author":"T Aoyama","year":"2023","unstructured":"Aoyama T, Maezawa Y, Hashimoto I et al (2023) Clinical impact of nutrition and inflammation assessment tools in pancreatic cancer treatment. Anticancer Res 43:3849\u20133860","journal-title":"Anticancer Res"},{"key":"2996_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21873\/invivo.13051","volume":"37","author":"T Aoyama","year":"2023","unstructured":"Aoyama T, Kazama K, Maezawa Y et al (2023) Usefulness of nutrition and inflammation assessment tools in esophageal cancer treatment. In Vivo 37:22\u201335","journal-title":"In Vivo"},{"key":"2996_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.809091","volume":"9","author":"J Mu","year":"2022","unstructured":"Mu J, Wu Y, Jiang C et al (2022) Progress in applicability of scoring systems based on nutritional and inflammatory parameters for ovarian cancer. Front Nutr 9:809091","journal-title":"Front Nutr"},{"key":"2996_CR17","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.21873\/anticanres.16023","volume":"42","author":"T Aoyama","year":"2022","unstructured":"Aoyama T, Hara K, Kazama K et al (2022) Clinical impact of nutrition and inflammation assessment tools in gastric cancer treatment. Anticancer Res 42:5167\u20135180","journal-title":"Anticancer Res"},{"key":"2996_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00280-023-04592-x","volume":"93","author":"S Goktas Aydin","year":"2024","unstructured":"Goktas Aydin S, Kutlu Y, Muglu H et al (2024) Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemother Pharmacol 93:71\u201378","journal-title":"Cancer Chemother Pharmacol"},{"key":"2996_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021318","author":"TH Wu","year":"2023","unstructured":"Wu TH, Tsai YT, Chen KY et al (2023) Utility of high-sensitivity modified Glasgow prognostic score in cancer prognosis: a systemic review and meta-analysis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24021318","journal-title":"Int J Mol Sci"},{"key":"2996_CR20","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.21037\/atm-21-4528","volume":"9","author":"L Yan","year":"2021","unstructured":"Yan L, Nakamura T, Casadei-Gardini A et al (2021) Long-term and short-term prognostic value of the prognostic nutritional index in cancer: a narrative review. Ann Transl Med 9:1630","journal-title":"Ann Transl Med"},{"key":"2996_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61061105","author":"H Taban","year":"2025","unstructured":"Taban H, Erman M, Guven DC et al (2025) Prognostic nutritional index and a blood-based prognostic tool in prostate cancer treated with abiraterone, enzalutamide or cabazitaxel. Medicina Kaunas. https:\/\/doi.org\/10.3390\/medicina61061105","journal-title":"Medicina Kaunas"},{"key":"2996_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115015","volume":"164","author":"M Nigam","year":"2023","unstructured":"Nigam M, Mishra AP, Deb VK et al (2023) Evaluation of the association of chronic inflammation and cancer: insights and implications. Biomed Pharmacother 164:115015","journal-title":"Biomed Pharmacother"},{"key":"2996_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/pros.20218","volume":"64","author":"SO Lee","year":"2005","unstructured":"Lee SO, Lou W, Nadiminty N et al (2005) Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64:160\u2013167","journal-title":"Prostate"},{"key":"2996_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/pros.23504","volume":"78","author":"SE Thomas-Jardin","year":"2018","unstructured":"Thomas-Jardin SE, Kanchwala MS, Jacob J et al (2018) Identification of an IL-1-induced gene expression pattern in AR(+) PCa cells that mimics the molecular phenotype of AR(-) PCa cells. Prostate 78:595\u2013606","journal-title":"Prostate"},{"key":"2996_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21976-w","volume":"12","author":"B Zhang","year":"2021","unstructured":"Zhang B, Li Y, Wu Q et al (2021) Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nat Commun 12:1714","journal-title":"Nat Commun"},{"key":"2996_CR26","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clgc.2013.04.020","volume":"11","author":"A Linton","year":"2013","unstructured":"Linton A, Pond G, Clarke S et al (2013) Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer 11:423\u2013430","journal-title":"Clin Genitourin Cancer"},{"key":"2996_CR27","doi-asserted-by":"publisher","first-page":"600 e609","DOI":"10.1016\/j.urolonc.2019.11.005","volume":"38","author":"J Stangl-Kremser","year":"2020","unstructured":"Stangl-Kremser J, Mari A, Suarez-Ibarrola R et al (2020) Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol 38:600 e609-600 e615","journal-title":"Urol Oncol"},{"key":"2996_CR28","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1007\/s00432-022-04220-w","volume":"149","author":"M Neuberger","year":"2023","unstructured":"Neuberger M, Goly N, Skladny J et al (2023) Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol 149:3371\u20133381","journal-title":"J Cancer Res Clin Oncol"},{"key":"2996_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00689-9","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Wang K, Ou Y et al (2023) Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-023-00689-9","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-02996-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-02996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:34:43Z","timestamp":1776843283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-02996-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2996"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-02996-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in accordance with the ethical standards established by the Declaration of Helsinki and was approved by the Kagawa University Ethics Committee (approval number: 2023\u2013047). The requirement for consent was waived because of the retrospective study design. In addition, information about the research was made publicly available, giving patients the option to opt out of having their medical data used in research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statements"}}]}}